卡格列净对2型糖尿病患者心血管保护作用的研究进展  

Cardiovascular Protection of Canagliflozin in Type 2 Diabetes Patients

作　　者：王菲 卢新政[2] WANG Fei;LU Xinzheng(The First Clinical Medical College of Nanjing Medical University,Department of Cardiology,Sir Run Run Hospital,Nanjing Medical University,Nanjing 210000,Jiangsu,China;Department of Cardiology,The First Affiliated Hospital of Nanjing Medical University,Nanjing 210000,Jiangsu,China)

机构地区：[1]南京医科大学第一临床医学院南京医科大学附属逸夫医院心内科,江苏南京210000 [2]南京医科大学第一附属医院心内科,江苏南京210000

出　　处：《心血管病学进展》2020年第3期231-234,共4页Advances in Cardiovascular Diseases

摘　　要：心血管并发症是2型糖尿病(T2DM)患者的主要并发症,也是其首要的死亡原因。因此在T2DM的治疗中,除了控制血糖外,预防患者的心血管并发症也尤为重要。大量临床和基础研究结果证实,钠-葡萄糖协同转运蛋白2抑制剂在降低血糖的同时,可减少心血管危险因素和心血管事件的发生。其中,卡格列净作为首个获得美国FDA批准的钠-葡萄糖协同转运蛋白2抑制剂类药物,其对T2DM患者的心血管保护作用已被研究证实。现主要针对卡格列净对T2DM患者心血管保护作用和可能的作用机制做一简要综述。Cardiovascular complications are a major complication of patients with type 2 diabetes(T2DM)and are the leading cause of death.In the treatment of T2DM,in addition to controlling blood glucose,it is especially important to prevent cardiovascular complications in patients.A large number of clinical and basic studies have confirmed that sodium-glucose cotransporter 2 inhibitors(SGLT-2 inhibitors)can reduce cardiovascular risk and reduce cardiovascular events while reducing blood glucose.As the first FDA-approved SGLT-2 inhibitor,canagliflozin has been confirmed that it can protect the cardiovascular system in patients with T2DM.This article is mainly aimed at a brief review of the cardiovascular protection and possible mechanisms of canagliflozin in patients with T2DM.

关 键 词：2型糖尿病 钠-葡萄糖协同转运蛋白2抑制剂 卡格列净 心血管并发症 

分 类 号：R587.2[医药卫生—内分泌] R54[医药卫生—内科学]